When would you use adjuvant abemaciclib in patients with clinically high-risk ER+, HER2-negative breast cancer, but pCR following neoadjuvant chemotherapy?

Patient is a post-menopausal woman with 4 lymph node mets that was strongly ER+/PR+, HER2-negative invasive ductal carcinoma with a high Ki-67 who achieved pCR to neoadjuvant AC+T

Answer from: Medical Oncologist at Academic Institution

This patient would not have qualified for the monarchE adjuvant abemaciclib protocol, which used pathologic staging for lymph node status (although baseline imaging was allowed for tumor size determination in patients who received adjuvant chemotherapy) (1). This is in contrast, for example, to the ...

Comments

Medical Oncologist at Alvin & Lois Lapidus Cancer Institute Northwest Hospital
In reviewing the treatment protocol attached to th...

Please select the option that best describes you:

When would you use adjuvant abemaciclib in patients with clinically high-risk ER+, HER2-negative breast cancer, but pCR following neoadjuvant chemotherapy?

Related Questions